Search results
Results from the WOW.Com Content Network
The efficacy of arsenic trioxide has also been demonstrated in the treatment of multiple myeloma, in combination with ascorbic acid [56] and bortezomib. [ 57 ] Animal studies have shown that the drug also affects ovarian, [ 58 ] liver, stomach, [ 59 ] prostate, and breast cancers, [ 60 ] as well as gliomas [ 61 ] and pancreatic cancer (in ...
Arsenic trioxide is indicated in combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia whose acute promyelocytic leukemia is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression; and for induction of remission and consolidation in patients with acute promyelocytic leukemia who are refractory to, or ...
Arsenic Trioxide (ATO) directly binds to GLI1 and GLI2 and inhibits the expression of target genes of the Hedgehog signaling pathway, thereby promoting cancer cell apoptosis and reducing cancer cell growth. [15] [50] ATO has been approved by the FDA for the treatment of acute promyelocytic leukemia.
Arsenic trioxide (As 2 O 3) inhibits cell growth and induces apoptosis (programmed cell death) in certain types of cancer cells, [23] which are normally immortal and can multiply without limit. In combination with all-trans retinoic acid , it is FDA-approved as first-line treatment for promyelocytic leukemia .
Breast cancer, lymphomas, ... Conditioning treatment before haematopoietic stem cell transplantation ... Arsenic trioxide [Note 2] IV:
Arsenic trioxide (As 2 O 3) is currently being evaluated for treatment of relapsed/refractory disease. Remission with arsenic trioxide has been reported. [23] Studies have shown arsenic reorganizes nuclear bodies and degrades the mutant PML-RAR fusion protein. [23] Arsenic also increases caspase activity which then induces apoptosis. [23]
"7+3" in the context of chemotherapy is an acronym for a chemotherapy regimen that is most often used today (as of 2014) as first-line induction therapy (to induce remission) in acute myelogenous leukemia, [1] [2] excluding the acute promyelocytic leukemia form, which is better treated with ATRA and/or arsenic trioxide and requires less chemotherapy (if requires it at all, which is not always ...
One very promising therapeutic agent for myelogenous leukemia and potentially other forms of cancer is arsenic trioxide (ATO). One study has been done showing that ATO treatment leads to specific degradation of the AML1/MDS1/EVI1 oncoprotein and induces both apoptosis and differentiation. [11]